James Watters
Overview
Explore the profile of James Watters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
895
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schonherr H, Ayaz P, Taylor A, Casaletto J, Toure B, Moustakas D, et al.
Proc Natl Acad Sci U S A
. 2024 Feb;
121(6):e2317756121.
PMID: 38300868
Fibroblast growth factor receptor (FGFR) kinase inhibitors have been shown to be effective in the treatment of intrahepatic cholangiocarcinoma and other advanced solid tumors harboring alterations, but the toxicity of...
2.
Varkaris A, Pazolli E, Gunaydin H, Wang Q, Pierce L, Boezio A, et al.
Cancer Discov
. 2023 Nov;
14(2):240-257.
PMID: 37916956
Significance: Treatments for PIK3CA-mutant cancers are limited by toxicities associated with the inhibition of WT PI3Kα. Molecular dynamics, cryo-electron microscopy, and DNA-encoded libraries were used to develop RLY-2608, a first-in-class...
3.
Subbiah V, Sahai V, Maglic D, Bruderek K, Toure B, Zhao S, et al.
Cancer Discov
. 2023 Jun;
13(9):2012-2031.
PMID: 37270847
Significance: Patients with FGFR2-driven cancers derive limited benefit from pan-FGFRi due to multiple FGFR1-4-mediated toxicities and acquired FGFR2 resistance mutations. RLY-4008 is a highly selective FGFR2 inhibitor that targets primary...
4.
Kappel C, Seely J, Watters J, Arnaout A, Cordeiro E
Can J Surg
. 2019 Sep;
62(5):358-360.
PMID: 31550104
The management of high-risk benign breast disease (BBD) is changing because of improvements in radiological and pathological analysis. We sought to determine the current practice recommendations of breast health professionals...
5.
Kim M, Ma D, Calligaris D, Zhang S, Feathers R, Vaubel R, et al.
Mol Cancer Ther
. 2018 Jul;
17(9):1893-1901.
PMID: 29970480
Controversy exists surrounding whether heterogeneous disruption of the blood-brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially...
6.
Jung J, Lee J, Dickson M, Schwartz G, Cesne A, Varga A, et al.
Nat Commun
. 2016 Sep;
7:12609.
PMID: 27576846
In tumours that harbour wild-type p53, p53 protein function is frequently disabled by the mouse double minute 2 protein (MDM2, or HDM2 in humans). Multiple HDM2 antagonists are currently in...
7.
Nunes M, Vrignaud P, Vacher S, Richon S, Lievre A, Cacheux W, et al.
Cancer Res
. 2015 Feb;
75(8):1560-6.
PMID: 25712343
Development of targeted therapeutics required translationally relevant preclinical models with well-characterized cancer genome alterations. Here, by studying 52 colorectal patient-derived tumor xenografts (PDX), we examined key molecular alterations of the...
8.
Huang S, Wang A, Greco R, Li Z, Barberis C, Tabart M, et al.
Oncotarget
. 2014 May;
5(10):3362-74.
PMID: 24830942
Inhibitors of JAK2 kinase are emerging as an important treatment modality for myeloproliferative neoplasms (MPN). However, similar to other kinase inhibitors, resistance to JAK2 inhibitors may eventually emerge through a...
9.
Arnaout A, Smylie J, Seely J, Robertson S, Knight K, Shin S, et al.
Ann Surg Oncol
. 2013 Aug;
20(10):3335-40.
PMID: 23975290
Background: The diagnostic phase of care is an anxiety-provoking and stressful experience for the potential breast cancer patient. A multidisciplinary team of breast cancer specialists embarked on a new initiative...
10.
Krop I, Demuth T, Guthrie T, Wen P, Mason W, Chinnaiyan P, et al.
J Clin Oncol
. 2012 May;
30(19):2307-13.
PMID: 22547604
Purpose: Aberrant Notch signaling has been implicated in the pathogenesis of many human cancers. MK-0752 is a potent, oral inhibitor of γ-secretase, an enzyme required for Notch pathway activation. Safety,...